Experian Assistant Wins 2025 FinTech Breakthrough Award for Analytics Innovation
Agentic AI-powered virtual assistant offers 24/7 analytics and modeling expertise, helps slash model-development times for financial institutions
Experian, a leading global data and technology company, today announced that Experian Assistant, an agentic AI-powered solution that greatly accelerates the data-modeling lifecycle, has won the 2025 FinTech Breakthrough Award for Analytics Innovation. For the second consecutive year, Experian received this prestigious award that recognizes those “who are dedicated to reshaping the FinTech industry and improving people’s lives through innovative technologies.”
Experian Assistant enables financial institutions to perform data exploration, build and deploy models, monitor their performance, and increase speed to market to launch new offerings. Integrated with Experian Ascend Platform™, the solution greatly accelerates the modeling lifecycle, slashing model-development times from months to days and — in some cases — hours.
“To stay ahead of their competition, financial institutions need a solution to quickly go from ideas to data and into production,” said Shri Santhanam, Executive Vice President and General Manager of Software, Platforms, and AI, Experian North America. “Like having an analytics and modeling expert by your side 24x7, Experian Assistant provides immediate responses to users’ questions, enhances model transparency, and helps quickly parse through multiple model iterations by selecting optimal modeling features along with coding and deployment support.”
The world’s largest financial Institutions use Experian’s Ascend Platform and – in close collaboration with several customers – Experian Assistant was developed to offer them a deeper understanding of credit data and provide best practices on how to optimally use analytics. It enables those institutions to broaden their scope of data and deploy advanced, agentic AI to effectively score a larger number of consumers. This improves their accuracy and inclusivity, and aligns with Experian's mission of fostering greater financial equity.
Experian Assistant advances regulatory compliance through automated model risk documentation, identity and fraud management, risk assessment and transaction monitoring.
This year’s 9th annual awards program received more than 4,500 nominations from all over the world. For more information on the 2025 FinTech Breakthrough Awards, visit: https://fintechbreakthrough.com/.
About Experian
Experian is a global data and technology company, powering opportunities for people and businesses around the world. We help to redefine lending practices, uncover and prevent fraud, simplify healthcare, deliver digital marketing solutions, and gain deeper insights into the automotive market, all using our unique combination of data, analytics and software. We also assist millions of people to realize their financial goals and help them to save time and money.
We operate across a range of markets, from financial services to healthcare, automotive, agribusiness, insurance, and many more industry segments.
We invest in talented people and new advanced technologies to unlock the power of data and innovate. As a FTSE 100 Index company listed on the London Stock Exchange (EXPN), we have a team of 22,500 people across 32 countries. Our corporate headquarters are in Dublin, Ireland. Learn more at experianplc.com.
Experian and the Experian marks used herein are trademarks or registered trademarks of Experian and its affiliates. Other product and company names mentioned herein are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250320296728/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Global udvider M&A- og værdiansættelseskapacitet i UAE28.3.2025 14:42:00 CET | Pressemeddelelse
Andersen Global udvider sin tilstedeværelse i Mellemøsten via en samarbejdsaftale med Ideal Capital, et M&A- og værdiansættelsesfirma i Dubai. Ideal Capital, der blev grundlagt i 2011 af Ramesh Mahalingam, har opbygget et omdømme via sin servicering af mere end 100 kunder, der inkluderer førende selskaber, statslige enheder og fremtrædende familiekontorer i regionen. Firmaet yder bistand og rådgivning om ledelse, værdiansættelse, transaktioner og bæredygtighed inden for så forskellige brancher som banker, uddannelse, sundhedspleje, fast ejendom, fremstilling, byggeri samt olie og gas. "Vi holder altid fokus på at skabe meningsfuld værdi for vores kunder," siger administrerende direktør Ramesh Mahalingam. "Ved at samarbejde med Andersen Global kan vi nu nå længere ud og nå flere forskellige brancher. Samarbejdet sætter os i stand til at give kunderne præcist tilpasset rådgivning og handlingsorienteret indsigt, der flugter med deres strategiske mål og skiftende markedsforhold. Ved at gå
Altasciences Receives 2025 CDMO Leadership Award in Small Molecule Dosage Form Category28.3.2025 14:22:00 CET | Press release
Altasciences, a nine-time CRO Leadership Award winner, is proud to announce they have been awarded a 2025 CDMO Leadership Award in the Small Molecule Dosage Form–North America category. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250327305519/en/ Altasciences receives a 2025 CDMO Leadership Award in the Small Molecule Dosage Form (North America) category. Altasciences’ CDMO site supports drug development with formulation, manufacturing, and analytical testing—from discovery to commercialization. Their FDA-inspected facility features Grade C cleanrooms, R&D and analytical labs, ICH stability chambers, and a cGMP warehouse. "This recognition reflects our CDMO team’s unwavering dedication and expertise, as well as our unrelenting commitment to advancing drug development in collaboration with leading pharmaceutical and biotech innovators,” says Marie-Hélène Raigneau, Co-Chief Operating Officer at Altasciences. “We are gratefu
SES and SpeQtral Sign MoU to Advance Global Quantum-Secure Communications28.3.2025 13:49:00 CET | Press release
An interoperable Optical Ground Station will provide a long-distance Quantum Key Distribution link between Asia and Europe to scale next-generation cybersecurity and services SES and SpeQtral signed a Memorandum of Understanding (MoU) to develop an interoperable Optical Ground Station (OGS) to establish long-distance satellite-based Quantum Key Distribution (QKD) between Asia and Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250328851677/en/ SES's CEO Adel Al-Saleh and SpeQtral's CEO Chune Yang Lum sign a Memorandum of Understanding to develop an interoperable Optical Ground Station to establish long-distance satellite-based Quantum Key Distribution between Asia and Europe. Under the agreement, the development of an interoperable OGS will enable SES and SpeQtral to connect both companies’ current and future QKD satellite missions, resulting in easier access to, and diversity in the supply of long-distance QKD to end
SBC Medical Group Holdings Inc. Announces Fourth Quarter and Full Year 2024 Financial Results28.3.2025 12:00:00 CET | Press release
SBC Medical Group Holdings Incorporated (NASDAQ: SBC, “SBC Medical” or the “Company”), a global owner, operator and provider of management services and products to cosmetic treatment centers, today announced its financial results for -the three months ended December 31, 2024 and full year 2024. Fourth Quarter 2024 HighlightsTotal revenues were $44 million, representing a 29% year-over-year decrease. Gross profit was $34 million, representing a 22% year-over-year decrease. Income from operations was $5 million, representing an 80% year-over-year decrease. EBITDA1, which is calculated by adding depreciation and amortization expense and impairment loss to income from operations was $21 million, representing a 22% year-over-year decrease. EBITDA margin1was 47% for the fourth quarter of 2024, compared to 43% for the fourth quarter of 2023. Net income attributable to SBC Medical Group was $7 million, representing a 54% year-over-year decrease. Earnings per share, which is defined as net inco
SINOVAC Announces New Board Member and Chairman of the Audit Committee28.3.2025 12:00:00 CET | Press release
Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that its board of directors (the “Board”) has appointed Sven H. Borho, CFA, as director to the Board to fill in a vacancy created by a recent resignation. As a qualified audit committee financial expert under Nasdaq Rule 5605, Mr. Borho has also been elected as the Chair of the Audit Committee of the Board. Mr. Borho is a founder and Managing Partner of OrbiMed and has over 30 years of experience investing in the healthcare sector. OrbiMed is a leading healthcare investment firm with approximately $17 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through a range of private equity funds, public equity funds and royalty/credit funds. OrbiMed funds have been shareholders of SINOVAC since 2013 and currently hold over 2.7 million shares. Following this appo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom